-+ 0.00%
-+ 0.00%
-+ 0.00%

On November 14, the National Health Insurance Administration announced the 2026 new version of the national medical insurance drug catalogue. The innovative anti-PD-1 monoclonal H drug independently developed by Fuhong Hanlin entered the national medical insurance catalogue for the first time. All 5 indications approved for marketing in China were included, covering core treatment fields such as lung cancer and gastrointestinal tumors. In addition, another innovative product, futokinin® first-line treatment of HR+/HER2- advanced breast cancer, was added to medical insurance. So far, all 8 products already marketed by Fuhong Hanlin in China have been included in the national medical insurance catalogue.

Zhitongcaijing·11/14/2026 12:17:01
Listen to the news
On November 14, the National Health Insurance Administration announced the 2026 new version of the national medical insurance drug catalogue. The innovative anti-PD-1 monoclonal H drug independently developed by Fuhong Hanlin entered the national medical insurance catalogue for the first time. All 5 indications approved for marketing in China were included, covering core treatment fields such as lung cancer and gastrointestinal tumors. In addition, another innovative product, futokinin® first-line treatment of HR+/HER2- advanced breast cancer, was added to medical insurance. So far, all 8 Fuhong Hanlin products that have been marketed in China have been included in the national medical insurance catalogue.